Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Moderna Inc (NASDAQ: MRNA) closed at $27.05 in the last session, up 1.84% from day before closing price of $26.56. In other words, the price has increased by $1.84 from its previous closing price. On the day, 12.86 million shares were traded.
Ratios:
We take a closer look at MRNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.14 and its Current Ratio is at 4.22. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on March 13, 2025, initiated with a Neutral rating and assigned the stock a target price of $40.
On February 18, 2025, Barclays Downgraded its rating to Equal Weight which previously was Overweight and also lowered its target price recommendation from $111 to $45.
Goldman Downgraded its Buy to Neutral on January 29, 2025, whereas the target price for the stock was revised from $99 to $51.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 03 ’25 when Bancel Stephane bought 160,314 shares for $31.22 per share. The transaction valued at 5,004,318 led to the insider holds 9,210,686 shares of the business.
SAGAN PAUL bought 31,620 shares of MRNA for $1,004,251 on Mar 03 ’25. The Director now owns 312,027 shares after completing the transaction at $31.76 per share. On Dec 09 ’24, another insider, Klinger Shannon Thyme, who serves as the Chief Legal Officer of the company, sold 529 shares for $44.68 each. As a result, the insider received 23,637 and left with 20,446 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.29 while its Price-to-Book (P/B) ratio in mrq is 1.04.
Stock Price History:
Over the past 52 weeks, MRNA has reached a high of $158.82, while it has fallen to a 52-week low of $23.15. The 50-Day Moving Average of the stock is 0.50%, while the 200-Day Moving Average is calculated to be -38.42%.
Shares Statistics:
A total of 387.00M shares are outstanding, with a floating share count of 342.49M. Insiders hold about 11.44% of the company’s shares, while institutions hold 72.17% stake in the company.
Earnings Estimates
As of right now, 12.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$1.81, with high estimates of -$1.25 and low estimates of -$2.5.
Analysts are recommending an EPS of between -$8.24 and -$11.4 for the fiscal current year, implying an average EPS of -$10.04. EPS for the following year is -$7.35, with 20.0 analysts recommending between -$1.27 and -$9.78.
Revenue Estimates
According to 13 analysts, the current quarter’s revenue is expected to be $116.85M. It ranges from a high estimate of $158M to a low estimate of $67.8M. As of the current estimate, Moderna Inc’s year-ago sales were $241MFor the next quarter, 13 analysts are estimating revenue of $1.16B. There is a high estimate of $1.48B for the next quarter, whereas the lowest estimate is $789.74M.
A total of 25 analysts have provided revenue estimates for MRNA’s current fiscal year. The highest revenue estimate was $2.46B, while the lowest revenue estimate was $1.57B, resulting in an average revenue estimate of $2.07B. In the same quarter a year ago, actual revenue was $3.24BBased on 25 analysts’ estimates, the company’s revenue will be $2.41B in the next fiscal year. The high estimate is $5.36B and the low estimate is $1.36B.
